KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track –– Formal Notification Received of Sebetralstat EU Orphan Drug Status –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused...
Source: pharmiweb.com